Market research
TMDX TransMedics Group Inc
NASDAQ USD Healthcare
Latest close
As of 29 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 2B
- P/E ratio
- 18.34
- Analyst target
- 98.7273
- Dividend yield
- Not available
- Beta
- 1.93
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- Not available
- Market cap
- 2B
- P/E ratio
- 18.34
- Analyst target
- 98.7273
- Dividend yield
- Not available
- Beta
- 1.93
About
About TransMedics Group Inc
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Research context
TransMedics Group Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Devices
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the TMDX discussion.
5 years, 6 months ago
TransMedics Group, Inc is currently in a long term uptrend where the price is trading 32.5% above its 200 day moving average.
From a valuation standpoint, the stock is 97.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 38.6.
TransMedics Group, Inc's total revenue rose by 25.9% to $8M since the same quarter in the previous year.
Its net income has increased by 31.2% to $-6M since the same quarter in the previous year.
Finally, its free cash flow grew by 2.0% to $-7M since the same quarter in the previous year.
Based on the above factors, TransMedics Group, Inc gets an overall score of 5/5.